Neutrophil/Lymphocyte and Platelet/lymphocyte Ratios as Predictors of Patient Response to Bevacizumab in Iraqi Patients with Metastatic Colorectal Cancer

Rasha Mahroos Faris; Mohammed Mahmood Mohammed; Ayman Adnan Delan

doi:10.54133/ajms.v7i1(Special).868

المؤلفون

Rasha Mahroos Faris Ramadi Maternity and Children Teaching Hospital, Anbar, Iraq https://orcid.org/0009-0002-8892-762X
Mohammed Mahmood Mohammed Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Ayman Adnan Delan Anbar Specialized Oncology Center, Anbar, Iraq https://orcid.org/0009-0007-7158-5543

DOI:

https://doi.org/10.54133/ajms.v7i1(Special).868

الكلمات المفتاحية:

Bevacizumab، Metastatic colorectal cancer، Neutrophil/lymphocyte ratio، Platelet/lymphocyte ratio

الملخص

Background: Global clinical trials have shown that bevacizumab, along with chemotherapy, is beneficial for people with metastatic colorectal cancer (mCRC). Nevertheless, there isn't a useful biomarker to predict its effectiveness. Objectives: The study's goal was to analyze and evaluate the practical pretreatment biomarker in people with metastatic colorectal cancer (mCRC) to predict bevacizumab efficacy. Methods: This study, which is retrospective, includes 157 patients diagnosed with mCRC who received bevacizumab in association with chemotherapy from three centers in Iraq. The study looked at how clinical data and biomarkers relate to disease control (DC), overall survival (OS), and progression-free survival (PFS). It also looked at how well they could predict these outcomes. The cutoff values of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were examined with ROC analysis. Results: For all patients, the median follow-up duration was 12 months. The PLR, NLR and median alkaline phosphatase (ALP) values were considerably lower in disease-control (DC) patients than in non-DC patients. The carcinoembryonic antigen (CEA) baseline level significantly correlated with shorter OS, while the ALP baseline level did not significantly correlate with shorter PFS. Among the clinical data, only multiple organ metastases showed a strong correlation with a shorter PFS and OS. Conclusions: A low pretreatment N/L ratio and P/L ratio might be good predictors of bevacizumab efficacy for metastatic colorectal cancer patients, and it could be clinically useful for choosing responders.

التنزيلات

بيانات التنزيل غير متوفرة بعد.

المراجع

Cancer [Internet]. WHO.int. 2021 [cited 8 December 2023]. Available at: www.who.int/news-room/fact-sheets/detail/cancer

Ibrahem S, Ahmed H, Zangana S. Trends in colorectal cancer in Iraq over two decades: incidence, mortality, topography and morphology. Ann Saudi Med. 2022 ;42(4):252-261. doi: 10.5144/0256-4947.2022.252.

Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacal Ther. 2010;87:401-406. doi: 10.1038/clpt.2009.312.

Krämer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32(1):1-14. doi: 10.1111/j.1365-2710.2007.00800. x.

Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):677. doi: 10.1186/s12885-016-2734-y.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol. 2011;49(10):1398-406. doi: 10.1055/s-0031-1281752.

Artaç M, Uysal M, Karaağaç M, Korkmaz L, Er Z, Güler T, et al. Prognostic impact of neutrophil/lymphocyte ratio, platelet count, CRP, and albumin levels in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab. J Gastrointest Cancer. 2017;48(2):176-180. doi: 10.1007/s12029-016-9879-4.

Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, et al. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol. 2009;20(8):1383-1386. doi: 10.1093/annonc/mdp012.

Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Sculli CM, et al. The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer. 2006;95(1):13-20. doi: 10.1038/sj.bjc.6603204.

Shitara K, Matsuo K, Yokota T, Takahari D, Shibata T, Ura T, et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res. 2011;4(5-6):168-172. PMID: 22295128.

Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, et al. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014;31(9):166. doi: 10.1007/s12032-014-0166-6.

Zhang H, Li W, Hu F, Sun Y, Hu T, Tong T. MR texture analysis: potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases. Abdom Radiol (NY). 2019;44(1):65-71. doi: 10.1007/s00261-018-1682-1.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 200945(2):228-247. Doi: 10.1016/j.ejca.2008.10.026.

Zhang Y, Jiang C, Li J, Sun J, Qu X. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma. Clin Transl Oncol. 2015;17(10):810-818. doi: 10.1007/s12094-015-1310-2.

Bozkurt O, Karaca H, Berk V, Inanc M, Ocak Duran A, Ozaslan E, et al. Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients. J BUON. 2015;20(6):1432-1439. PMID: 26854438.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-886. doi: 10.1038/nature01322.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. doi: 10.1016/j.cell.2010.01.025.

Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576-590. doi: 10.1016/j.ccr.2011.09.009.

Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130-137. doi: 10.1016/j.ccr.2013.05.008.

Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446–3458. doi: 10.1172/JCI67484.

Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015;22(4):1377-1384. doi: 10.1245/s10434-014-4097-4.

De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012;12(4):264-269. doi: 10.1016/j.clbc.2012.04.004.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. doi: 10.1038/nature07205.

Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer. 2013;109(2):395-400. doi: 10.1038/bjc.2013.346.

Shen J, Zhu Y, Wu W, Zhang L, Ju H, Fan Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit. 2017;23:315-324. doi: 10.12659/msm.902752.

Zhang X, Li J, Peng Q, Huang Y, Tang L, Zhuang Q, et al. Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy. Cancer Manag Res. 2018;11:191-199. doi: 10.2147/CMAR.S187559.

Haram A, Boland MR, Kelly ME, Bolger JC, Waldron RM, Kerin MJ. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review. J Surg Oncol. 2017;115(4):470-479. d: 10.1002/jso.24523.

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29(4):924-930. doi: 10.1093/annonc/mdy004.

Saif MW, Alexander D, Wicox CM. Serum alkaline phosphatase level as a prognostic tool in colorectal cancer: A study of 105 patients. J Appl Res. 2005;5(1):88-95. PMID: 19750205;

Maisano R, Azzarello D, Del Medico P, Maisano M, Bottari M, Egitto G, et al. Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a mono institutional retrospective study. Tumori. 2011;97(1):39-42. doi: 10.1177/030089161109700108.

Zaher DM, El-Gamal MI, Omar HA, Aljareh SN, Al-Shamma SA, Ali AJ, Zaib S, et al. Recent advances with alkaline phosphatase isoenzymes and their inhibitors. Arch Pharm (Weinheim). 2020 May;353(5): e2000011. Doi: 10.1002/ardp.202000011. Epub 2020 Mar 4. PMID: 32128876.

Jiang Y, Li X, Walt DR. Single-molecule analysis determines isozymes of human alkaline phosphatase in serum. Angew Chem Int Ed Engl. 2020;59(41):18010-18015. doi: 10.1002/anie.202007477.

Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors? Transl Cancer Res. 2023;12(10):2932-2945. doi: 10.21037/tcr-23-1190.

Elias D, Sideris L, Pocard M, de Baere T, Dromain C, Lassau N, et al. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol. 2005;12(4):298-302. doi: 10.1245/ASO.2005.03.020.

Carpizo DR, D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009;10(8):801-809. doi: 10.1016/S1470-2045(09)70081-6.

Wagener C, Ergün S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp Cell Res. 2000;261(1):19-24. doi: 10.1006/excr.2000.5038.

Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308-317. doi: 10.1093/annonc/mdf034.